STVN:NYE-Stevanato Group SpA (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 26.45

Change

0.00 (0.00)%

Market Cap

USD 7.29B

Volume

0.28M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-05 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

N/A

USD 66.12B
ALC Alcon AG

N/A

USD 44.24B
HYB New America High Income Closed..

N/A

USD 35.93B
RMD ResMed Inc

N/A

USD 32.13B
WST West Pharmaceutical Services I..

N/A

USD 24.28B
BAX Baxter International Inc

N/A

USD 17.27B
TFX Teleflex Incorporated

N/A

USD 10.04B
ATR AptarGroup Inc

N/A

USD 9.81B
BLCO Bausch + Lomb Corp

N/A

USD 5.28B
HAE Haemonetics Corporation

N/A

USD 4.86B

ETFs Containing STVN

BNC:CA 13.14 % 0.68 %

N/A

N/A
RBNK:CA RBC Canadian Bank Yield I.. 8.46 % 0.33 %

N/A

CAD 0.25B
HCB:CA 6.95 % 0.65 %

N/A

N/A
BFIN-U:CA 5.72 % 0.00 %

N/A

N/A
INOC:CA Global X Inovestor Canadi.. 4.07 % 0.66 %

N/A

CAD 0.03B
MCLC:CA Manulife Multifactor Cana.. 3.34 % 0.45 %

N/A

CAD 0.34B
XESG:CA iShares ESG Aware MSCI Ca.. 3.30 % 0.00 %

N/A

CAD 0.39B
FBE:CA 2.65 % 0.83 %

N/A

N/A
DXIF:CA Dynamic Active Internatio.. 0.00 % 0.00 %

N/A

CAD 4.90M

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.08% 50% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.08% 50% F 23% F
Trailing 12 Months  
Capital Gain -1.49% 56% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.49% 56% F 23% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 22.45% 84% B 86% B+
Dividend Return 22.45% 84% B 84% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 40.59% 42% F 25% F
Risk Adjusted Return 55.29% 84% B 79% B-
Market Capitalization 7.29B 56% F 81% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.